伊立替康联合卡培他滨治疗晚期大肠癌的临床观察.docxVIP

伊立替康联合卡培他滨治疗晚期大肠癌的临床观察 南京江北人民医院肿瘤科江苏南京210048 摘要目的：观察伊立替康(CPT-11)联合卡培他滨治疗转移性结直肠癌的疗效 和不良反应。方法：70例均为失去手术或再次手术治疗机会的有可测量病灶的 晚期大肠癌患者。行CPT-11联合卡培他滨治疗,CPT-11180mg/m2静脉滴注90min, 第1天；卡培他滨1250mg/m2 , 2次/天，第KL4天口服，休息7天，每3周 重复为1个周期，2个周期后评价疗效。结果：70例均可评价疗效及不良反应。 完全缓解(CR)为6,部分缓解(PR)为25例，有效率(RR)为44.2% (31/70), 稳定(SD) 27例，进展(PD)为12例。中位疾病进展时间7.2月(6?21月)， 中位生存期10.5个月。不良反应为恶心呕吐、粒细胞减少、厌食、乏力、脱发 和迟发性腹泻，多为1?11度。结论：伊立替康联合卡培他滨方案治疗晚期大肠 癌，用药方便，疗效确切，不良反应患者均能耐受，可广泛应用于临床。 关键词：伊立替康；卡培他滨；晚期大肠癌；化疗 Observing the Effect of Irinotean Combined with Capecitabine Regimen on Patients with Metastatic Colorectal Cancer Song Meihua, Fengge, Gao Jingfeng Nanjing Jiangbei People Hospitab Nanjing Jiangsu 210048 China Abstract Objective： To observe the clinical efficacy and safety of Irinotecan(CPT-11) combine with capecitabine in metastatic colorectal cancer. Methods： Seventy patients with metastatic colorectal cancer who have lost the oppourtunity to surgery.They have measurable lesi on .They were treated with CPT-11180mg/m2 ivgtt dl, and capectabine 1250mg/m2middot;d, twice a day for 14 days. 21 days was one cycle.The effect was evaluated after two cycles. Results： 70 patients were assessable to observe the efficacy and safety.6 case were CR(6/70), 25 case were PR(25/70), respose rate was 44.2% (31/70), 27 case were SD(27/70), 12 case were PD(12/70).Median time to progression were 7.2 months(6 to 21 months), median overall survival was 10.5months.The majority of adverse reaction were nausea, vomiting，anorexia t leucopenia and alopecia.Most of them were I / II degree.Conclusion： The combined chemotherapy with irinotecan and capecitabine has a high therapeutic respongse with acceptable toxicity in patients with metastatic colorectal cancer, and which was convenient to administer with definite efficacyJt could be extensively used.. Keywords： irinotecan； capecitabine； metastatic colorectal cancer； chemotherapy 前言 大肠癌是严重威胁人类健康的消化系统恶性肿瘤，随诊人们生活水平的 提高和生活方式的改变，其发病率和死亡率呈逐年上升趋势［1］。目前，大肠癌 的治疗仍然以根治性手术为首选，对于无法行根治手术及术后出现复发转移的